1 |
Li Z, Zou J, Cao D, Ma X. Pharmacological basis of tanshinone and new insights into tanshinone as a multitarget natural product for multifaceted diseases. Biomed Pharmacother 2020;130:110599. [PMID: 33236719 DOI: 10.1016/j.biopha.2020.110599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
2 |
Wang B, Hong L, Liu Y, Bedingfield SK, Zhang C, Peng C, Qian J, Zha L. Preparation, preliminary pharmacokinetics and brain tissue distribution of Tanshinone IIA and Tetramethylpyrazine composite nanoemulsions. Pharm Dev Technol 2019;24:1236-42. [PMID: 31407940 DOI: 10.1080/10837450.2019.1656237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Liu Y, Tong C, Tang Y, Cong P, Liu Y, Shi X, Shi L, Zhao Y, Jin H, Li J, Hou M. Tanshinone IIA alleviates blast-induced inflammation, oxidative stress and apoptosis in mice partly by inhibiting the PI3K/Akt/FoxO1 signaling pathway. Free Radic Biol Med 2020;152:52-60. [PMID: 32131025 DOI: 10.1016/j.freeradbiomed.2020.02.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
4 |
Wang X, Xu X, Guo Y, Huang P, Ha Y, Zhang R, Bai Y, Cui X, He S, Liu Q. Qiang Xin 1 Formula Suppresses Excessive Pro-Inflammatory Cytokine Responses and Microglia Activation to Prevent Cognitive Impairment and Emotional Dysfunctions in Experimental Sepsis. Front Pharmacol 2020;11:579. [PMID: 32457609 DOI: 10.3389/fphar.2020.00579] [Reference Citation Analysis]
|